Since 2011 the company has been among the top ten pharmaceutical companies in Russia in terms of production, and its sales turnover increases every year.
In April 2016 it announced plans to start production of original drugs that will be specially designed for supply to the US and the European Union markets.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze